

**IN THE CLAIMS:**

Claims 1-9 (canceled)

Claim 10 (currently amended): A method of inhibiting B-cell growth in an animal comprising the step of administering a therapeutically effective amount of an anti-BAFF antibody specific for BAFF ligand that recognizes human (SEQ ID NO:1) or murine (SEQ ID NO:2) BAFF ~~or an antigenic determinant thereof~~.

Claim 11 (currently amended): A method of inhibiting immunoglobulin production in an animal comprising the step of administering a therapeutically effective amount of an anti-BAFF antibody specific for BAFF ligand that recognizes human (SEQ ID NO:1) or murine (SEQ ID NO:2) BAFF ~~or an antigenic determinant thereof~~.

Claim 12 (currently amended): A method of co-inhibiting B-cell growth and immunoglobulin production in an animal comprising the step of administering a therapeutically effective amount of an anti-BAFF antibody specific for BAFF ligand that recognizes human (SEQ ID NO:1) or murine (SEQ ID NO:2) BAFF ~~or an antigenic determinant thereof~~.

Claim 13 (currently amended): A method of inhibiting ~~dendritic cell-induced~~ B-cell growth and maturation in an animal comprising the step of administering a therapeutically effective amount of an anti-BAFF antibody specific for BAFF ligand that recognizes human (SEQ ID NO:1) or murine (SEQ ID NO:2) BAFF ~~or an antigenic determinant thereof~~.

Claims 14-15 (canceled)

Claim 16 (original): The method according to claims 10-13, wherein the anti-BAFF ~~receptor~~ antibody is a monoclonal antibody.

Claims 17-50 (canceled)

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com